These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33645009)

  • 1. High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation.
    Huang R; Liu Y; Wang K; Wang Z; Zhang C; Zhang W; Zhao Z; Li G; Huang L; Chang Y; Zeng F; Jiang T; Hu H
    CNS Neurosci Ther; 2021 May; 27(5):617-628. PubMed ID: 33645009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
    Bao ZS; Chen HM; Yang MY; Zhang CB; Yu K; Ye WL; Hu BQ; Yan W; Zhang W; Akers J; Ramakrishnan V; Li J; Carter B; Liu YW; Hu HM; Wang Z; Li MY; Yao K; Qiu XG; Kang CS; You YP; Fan XL; Song WS; Li RQ; Su XD; Chen CC; Jiang T
    Genome Res; 2014 Nov; 24(11):1765-73. PubMed ID: 25135958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PTPRZ1-MET/STAT3/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization.
    Wang Y; Suo J; Wang Z; Ran K; Tian Y; Han W; Liu Y; Peng X
    Cell Signal; 2024 Aug; 120():111191. PubMed ID: 38685521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.
    Chen HM; Yu K; Tang XY; Bao ZS; Jiang T; Fan XL; Chen XW; Su XD
    FEBS Lett; 2015 Jun; 589(13):1437-43. PubMed ID: 25935522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastomas harboring gene fusions detected by next-generation sequencing.
    Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
    Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
    Zeng AL; Yan W; Liu YW; Wang Z; Hu Q; Nie E; Zhou X; Li R; Wang XF; Jiang T; You YP
    Oncogene; 2017 Sep; 36(38):5369-5381. PubMed ID: 28504721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel PTPRZ1-ETV1 fusion in gliomas.
    Matjašič A; Zupan A; Boštjančič E; Pižem J; Popović M; Kolenc D
    Brain Pathol; 2020 Mar; 30(2):226-234. PubMed ID: 31381204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.
    Hu H; Mu Q; Bao Z; Chen Y; Liu Y; Chen J; Wang K; Wang Z; Nam Y; Jiang B; Sa JK; Cho HJ; Her NG; Zhang C; Zhao Z; Zhang Y; Zeng F; Wu F; Kang X; Liu Y; Qian Z; Wang Z; Huang R; Wang Q; Zhang W; Qiu X; Li W; Nam DH; Fan X; Wang J; Jiang T
    Cell; 2018 Nov; 175(6):1665-1678.e18. PubMed ID: 30343896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
    International Cancer Genome Consortium PedBrain Tumor Project
    Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme.
    Chen BS; Wang KY; Yu SQ; Zhang CB; Li GZ; Wang ZL; Bao ZS
    Oncol Lett; 2020 Nov; 20(5):187. PubMed ID: 32952656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting gene fusions in glioma.
    Kim PL
    Curr Opin Neurol; 2021 Dec; 34(6):840-847. PubMed ID: 34766555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.
    Zuckermann M; He C; Andrews J; Bagchi A; Sloan-Henry R; Bianski B; Xie J; Wang Y; Twarog N; Onar-Thomas A; Ernst KJ; Yang L; Li Y; Zhu X; Ocasio JK; Budd KM; Dalton J; Li X; Chepyala D; Zhang J; Xu K; Hover L; Roach JT; Chan KC; Hofmann N; McKinnon PJ; Pfister SM; Shelat AA; Rankovic Z; Freeman BB; Chiang J; Jones DTW; Tinkle CL; Baker SJ
    Mol Cancer; 2024 Jun; 23(1):123. PubMed ID: 38849845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.
    Chai RC; Liu X; Pang B; Liu YQ; Li JJ; Li YF; Zhao Z; Du J; Bao ZS; Jiang T
    Cancer Sci; 2022 Feb; 113(2):796-801. PubMed ID: 34812554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MET fusions in solid tumors: A multicenter, large scale study in China.
    Yang W; Zhao X; Zheng A; Liu Z; Ma J; Zhang X; Li W; Wang D; Zhu J; Tao H; Zhang Y; Ma T; Liu Q
    Int J Cancer; 2023 Mar; 152(6):1259-1268. PubMed ID: 36408924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-1261/circ-PTPRZ1/PAK1 pathway regulates glioma cell growth and invasion.
    Zhang F; Mai SR; Cao FP; Cao CX; Zhang L
    Hum Cell; 2019 Oct; 32(4):540-547. PubMed ID: 31364003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-institutional series of a novel, recurrent TRIM24::MET fusion-driven infant-type hemispheric glioma reveals significant clinico-pathological heterogeneity.
    Gorodezki D; Chiang J; Viaene AN; Sievers P; Schmid S; Holzer U; Paulsen F; Schuhmann MU; Witt O; Schittenhelm J; Ebinger M
    Acta Neuropathol Commun; 2024 Jun; 12(1):101. PubMed ID: 38902810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic Fusions in Gliomas: An Institutional Experience.
    Polivka J; Svajdler M; Priban V; Mracek J; Kasik P; Martinek P; Ptakova N; Sharif Bagheri M; Shetti D; Pesta M; Potuznik P; Topolcan O
    Anticancer Res; 2022 Apr; 42(4):1933-1939. PubMed ID: 35347013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.
    Zhang Y; Farenholtz KE; Yang Y; Guessous F; Dipierro CG; Calvert VS; Deng J; Schiff D; Xin W; Lee JK; Purow B; Christensen J; Petricoin E; Abounader R
    Clin Cancer Res; 2013 Mar; 19(6):1433-44. PubMed ID: 23386689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.
    Kim KH; Seol HJ; Kim EH; Rheey J; Jin HJ; Lee Y; Joo KM; Lee J; Nam DH
    Neuro Oncol; 2013 Feb; 15(2):161-71. PubMed ID: 23258844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial.
    Bao Z; Li S; Wang L; Zhang B; Zhang P; Shi H; Qiu X; Jiang T
    Chin Neurosurg J; 2023 Jul; 9(1):21. PubMed ID: 37443050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.